ESMO2026速報！PD-L1陰性の進行非扁平NSCLCで、sacituzumab tirumotecan＋ペムブロリズマブが標準治療を大幅に上回る結果が中国のフェーズ3試験で示される。PFS中央値は15.0カ月 vs 5.7カ月（HR 0.49）。新たな1次治療の有力候補に。#ESMO26
https://medical.nikkeibp.co.jp/leaf/all/cancernavi/news/202610/595014.html
20 浏览 · 0 赞 · 0 转发 · 0 回复
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgTroFuse-021/ENGOT-ov85/GOG-3102: Phase 3 study of maintenance sacituzumab tirumotecan (Sac-TMT) with or without bevacizumab versus standard of care in patients with advanced ovarian cancer
https://esmocongress.esmo.orgNeoadjuvant sacituzumab govitecan plus pembrolizumab in resectable non-small cell lung cancer: Phase II CITADEL study
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.org来源：がんナビ通信 · x.com